04.01.03
Novatreat., Turku, Finland, has exercised its right to terminate the license and supply agreement it previously entered into with ImmuCell Corporation, Portland, ME, in March 2001. Novatreat, a licensee of certain nutritional rights of the company’s milk processing technology outside North America, has paid a $400,000 termination fee. It had previously paid the company $100,000 in license fees since entering into the agreement.
In other news, CURx Pharma, Evanston, IL, has entered into a separate license agreement for ImmuCell’s DiffGAM technology. The license covers pharmaceutical rights to the company’s patented colonic delivery technology outside of Europe as well as certain nutritional rights in North America.
In other news, CURx Pharma, Evanston, IL, has entered into a separate license agreement for ImmuCell’s DiffGAM technology. The license covers pharmaceutical rights to the company’s patented colonic delivery technology outside of Europe as well as certain nutritional rights in North America.